STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #571 by analyst upside · 2026-09-16
LEGN
Legend Biotech Corporation
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+174.4%
implied upside to consensus target
Current Price $17.67
Consensus Target $48.48
Bull Target $74.0
Bear Target $24.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
4
Hold
5
Sell
0
52-Week Low $16.24
52-Week High $37.5
YTD Return -17.9%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E 16.8x
EPS (TTM) $-0.48
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.3B
Profit Margin -7.2%
52-WEEK RANGE
52-Week Low $16.24
52-Week High $37.5
Current Price $17.67
Bear Target $24.0
Bull Target $74.0
● Now $17.67 ● Target $48.48
TRADING DATA
Avg Volume 2.4M
YTD Return -17.9%
Analyst Count 14
Consensus Buy
Upside to Target +174.4%
Last Updated 2026-09-16

ANALYST SUMMARY

Legend Biotech Corporation (LEGN) is currently trading at $17.67 with a Wall Street consensus price target of $48.48, implying potential upside of 174.4% over the next 12 months. 14 analysts currently cover LEGN, with a consensus rating of Buy - 64% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $74.0, while the most cautious has a target of $24.0.

LEGN operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 17.9% year-to-date and is currently trading near the lower end of its 52-week range of $16.24 – $37.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LEGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-09-11 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-04 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-08-12 Building track record
TD Cowen - Reiterated
Hold → Hold 2026-08-12 Building track record
Oppenheimer ↓ Downgrade
Outperform → Perform 2026-08-12 14% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-12 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-08-12 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-07-28 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
35
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →